RealRate

PHARMACEUTICAL 2023

MADRIGAL PHARMACEUTICALS INC. Rank 353 of 446



Selling, General and Administrative Cost of Goods Sold 6.19% Research and Development -36.8% Intangible Assets -23.8% Assets, Current 4.81% Property and Equipment -13.4% Other Assets -36.6% Expense 25.4% 25.4% 4.81% -36.6% -13.4% Liabilities, Non-Current -3.98% Other Liabilities 21.2% Liabilities. Other Net -25.6% 86.8% -1.20% 21.2% -3.98% -0.937% Liabilities 17.1% 23.4% -114% -11.5% Stockholders Equity -37.5% -4.86% -37.5% 113% Economic Capital Ratio -119%



RealRate

PHARMACEUTICAL 2023

MADRIGAL PHARMACEUTICALS INC.



Rank 353 of 446

The relative strengths and weaknesses of MADRIGAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MADRIGAL PHARMACEUTICALS INC. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 25% points. The greatest weakness of MADRIGAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is -76%, being 119% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	361,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	115,894
Liabilities, Non-Current	49,289
Other Assets	602
Other Compr. Net Income	48
Other Expenses	249,405
Other Liabilities	0
Other Net Income	2,185
Other Revenues	0
Property and Equipment	601
Research and Development	245,441
Selling, General and Administrative Expense	48,130

Output Variable	Value in 1000 USD
Assets	362,572
Liabilities	165,183
Expenses	542,976
Revenues	0
Stockholders Equity	197,389
Net Income	-540,791
Comprehensive Net Income	-540,767
Economic Capital Ratio	-76%

